Allogeneic peripheral blood stem cells transplantation (PBSCT) mobilized with recombinant human granulocyte colony-stimulating factor (G-CSF) has increased significantly during the last few years because of its several advantages over the use of bone marrow graft. These advantages include the higher yield of CD34-positive cells, earlier engraftment after transplantation, and no need for anesthesia and bone puncture. 1 Although some severe adverse effects such as thrombotic complications, interstitial pneumonia, or splenic rupture have been reported, 2 the short-term complications during the administration of G-CSF and apheresis seem in general to be more tolerable compared with the bone marrow harvesting procedure.
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On the other hand, long-term complications associated with G-CSF treatment have not been well investigated.
Among the long-term adverse effects of G-CSF treatment, the possible property of G-CSF to increase the risk of leukemia has been a matter of great interest. 3 We report here the first case of a healthy donor who developed acute myelogenous leukemia (AML) after G-CSF-primed PBSC harvest.
Case report
In September 2001, a 61-year-old female was admitted as a PBSCT donor for her younger brother, whose multiple myeloma had progressed. She had always been in excellent health except for allergies to some foods, including mackerel, and to some drugs. Her hematologic examination, performed approximately 2 months before the apheresis (10 July, 2001 ), showed a slightly low WBC count (3.69 Â 10 9 /l) with normal differential count, hemoglobin 14.8 g/dl, and platelet count 201 Â 10 9 /l (Table 1) . A WBC count just before G-CSF administration had returned to normal range (4.11 Â 10 9 /l). G-CSF was administered subcutaneously from 6 to 11 September (300 mg on September 6 and 11 and 300 mg twice a day from 7 to 10 September), in accordance with the protocol approved by the Ministry of Health, Labor and Welfare in Japan. PBSC were harvested on 10 and 11 September using Cobe Spectra s and a total of 1.35 Â 10 8 of CD34-positive cells were collected. She was discharged from the hospital without having experienced any complications, but declined the hospital's request for follow-up. The apheresis products were transfused to her brother and resulted in successful trilineage engraftment. However, the recipient later died from a relapse of his disease. A chromosome abnormality of recipient origin at the onset of the multiple myeloma was detected in 95% of bone marrow cells during his relapse.
On 9 July 2002, the donor was asymptomatic when she underwent a routine health checkup; WBC count was 3.30 Â 10 9 /l (differential count unavailable), hemoglobin 12.8 g/dl, and platelet count 206 Â 10 9 /l. However, beginning 18 November, she suffered from a low-grade fever and general fatigue. On 21 November, she was admitted to Fuchu hospital because of high fever, frequent vomiting, and leukocytosis (121.5 Â 10 9 /l). At admission, vital signs were temperature 39.51C, blood pressure 109/51 mmHg, and heart rate 120/min. C reactive protein (CRP) was elevated to 12.8 mg/dl with clinical signs of acute pneumonia. In addition, she had a generalized body rash, presumably an allergic reaction to vitamins prescribed by her family physician. Her peripheral WBC count was 125 Â 10 9 /l with 98.5% blastoid cells, hemoglobin 11.6 g/dl, platelet count 29 Â 10 9 /l, and LDH 349 IU/l (normal range, 106-211 IU/l). Bone marrow aspiration revealed a mononuclear cell count of 398.8 Â 10 9 /l with a marked increase in peroxidase-positive blastoid cells, with morphologies characteristic of AML (M1), according to FAB classifications ( Figure 1 ). With flow cytometric analysis, leukemia cells were positive for CD13 and 33 and were negative for CD14, 16, 34, 41a, 56, HLA-DR, and lymphoid markers. No chromosomal abnormality was found in these leukemia cells. WT-1 mRNA levels 4 in peripheral blood were extremely elevated (160 000 copies/mg RNA).
On the next day, daunorubicin (40 mg) was administered for 2 days to reduce the leukemic cells while preventing severe tumor lysis syndrome. Nevertheless, on day 5 of chemotherapy, the WBC count rapidly decreased from 165.8 Â 10 9 /l to 0.3 Â 10 9 /l. Before hematopoietic recovery was obtained, her pneumonia progressed rapidly and she died of respiratory failure on 1 December.
Materials and methods

Detection of G-CSF receptor
To detect the G-CSF receptors on her peripheral leukemic cells, we used three different approaches, including reverse transcription-polymerase chain reaction (RT-PCR), flow cytometry, and radio-receptor assay. For RT-PCR of G-CSF receptor, mononuclear cells were isolated using density gradient centrifugation on Ficoll-Paque (Pharmacia). After confirming microscopically that the cells exclusively consisted of leukemic cells, total RNA was extracted using a commercially available kit (RNAeasy, Qiagen), followed by RT using another kit (Omniscript, Qiagen). The cDNA was then subjected to PCR using upper primers (5 0 -ATGGAGGAGGATGCCTTCC-3 0 ) and lower primers (5 0 -TGGTGCCAGACTGGGATTG-3 0 ).
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For flow cytometric analysis, anti-CD114 antibodies conjugated with biotin and FITC-conjugated avidin were used as previously described. 6 To evaluate the expression of cell surface receptor for G-CSF in the leukemic cells of this patient, G-CSF was iodinated using the lactoperoxidase method. 7 In vitro growth properties Standard MTT assay was performed for leukemia cells obtained from peripheral blood samples as previously described. 8 Cells were cultured on 96-well plates at 1 Â 10 5 / well in 100 ml of RPMI/10% FCS either with G-CSF, granulocyte-macrophage-CSF (GM-CSF), interleukin-3 (IL-3), or stem cell factor (SCF) (50 ng/ml) for 36, 60, and 84 h, followed by further incubation with 10 ml of MTT (5 mg/ml) for 4 h. After lysing with 0.04 N HCl/isopropanol, the lysate was measured with a microplate reader for OD 570 nm against OD 630 nm. To obtain the growth curves, the leukemic cells were cultivated in RPMI containing 10% FCS in 25 cm 2 flasks with (1) no cytokine, (2) SCF (10 ng/ml), (3) G-CSF (10 ng/ml), (4) SCF and G-CSF, or (5) SCF, G-CSF, and IL-3 (10 ng/ml).
Results
With RT-PCR analysis for G-CSF receptor, a single sharp band was obtained with a size compatible with G-CSF receptor cDNA, suggesting the expression of G-CSF receptor mRNA from the patient's leukemic cells (Figure 2) . From flow cytometric analysis using anti-CD114 antibodies, however, only a small portion (4.2%) of the leukemia cells were positive for G-CSF receptors, presumably due to the extremely low frequency of the receptor on the cell surface. 6 Similarly, the radio-receptor assay results were positive in only small portions of cells (data not shown).
With MTT assays, on the other hand, leukemia cells responded to all of the cytokines tested in the present study, with the response to G-CSF being the most apparent ( Figure 3a) . As shown in Figure 3b , growth curve analysis showed that the effects of G-CSF alone on the leukemic cells were likely to be as a 'survival factor' rather than as a growth promoting factor. These G-CSF effects were comparable, or even stronger than those of SCF alone. SCF or SCF plus IL-3 synergistically affected the leukemic cells with G-CSF and transiently stimulated their growth. However, none of the conditions used in this study was able to keep them growing for longer than 2 weeks.
Discussion
We report here the first case of a healthy donor who developed AML, presumably 14 months after G-CSFprimed PBSC harvest. Although it was also possible that the patient already had the disease at the time of a health checkup (10 months after the donation), when mildly decreased WBC and hemoglobin were noted, no detailed information, including blood smears at the time of donation or of health checkup, was available.
Her leukemia cells did express G-CSF receptors and further studies with cell cultures suggested that G-CSF is able to support proliferation and survival of AML cells. According to previous reports, although the expression of G-CSF receptors is found in 97% of AML cases, a proliferative response to exogenous G-CSF, as seen in our case, is restricted to about 67% of cases. 9 These observations may be of importance in that the possible contribution of G-CSF to leukemogenesis, by a mechanism such as the selection of leukemic cells already present at the time of donation, 3 could not be completely excluded. In addition, it might have indirectly caused leukemic transformation of normal precursor cells de novo via an unusual promotion of the cycling of myeloid progenitor cells, thereby increasing the risk of replication errors.
In general, however, previous findings suggest a minor role for G-CSF as a leukemogenic agent. For instance, although possible roles are suggested for exogenous GM-CSF during the progression from myelodysplastic syndrome (MDS) to AML, this is not the case for G-CSF. 10 Furthermore, in a series of studies to monitor long-term adverse effects of G-CSF administration in donors (each study consists of 3-281 donors with mean follow-up of 1-5 years), no donors subsequently develop leukemia. [11] [12] [13] [14] [15] However, the information available to date is extremely limited if based on the calculation by Hasenclever et al 3 that more than 10 years of follow-up of 2000 donors is required to determine statistically a 10-fold increase in the risk of leukemia. There is no detailed information on the number of allogeneic PBSC transfusions performed worldwide. In Japan, the Japanese Society of Hematopoietic Stem Cell Transplantation has to date collected and analyzed the follow-up data of more than 2000 PBSCT donors. A series of reports presented by the European Group for Blood and Marrow Transplant (EBMT) shows that approximately 14 000 allogeneic PBSC transfusions were performed from 1996 to 2001 in Europe and Israel with an estimated mean follow-up duration of 2.8 years as of 2002. [16] [17] [18] [19] [20] On the other hand, since 1994, 19 938 allogeneic peripheral blood stem cell transplants have been registered with the International Bone Marrow Transplant Registry (IBMTR); 44% were done in North America, 4% in South America, 33% in Europe, 5% in Australia/New Zealand, 8% in Africa/the Middle East, and 6% in Asia. We estimated that this represents 40-50% of the total number done worldwide, thus making a total number 40 000-50 000. Therefore, if the median follow-up duration of these cases was estimated as 2-3 years, there are 80 000-150 000 patient years of observation. If the natural incidence of acute leukemia was around five cases per 100 000 patient years, 3 we would expect to have seen 4-7.5 cases of acute leukemia in these donors. Thus, if our case is truly the first in the world, the incidence of leukemia in donors may not be higher than that of naturally occurring leukemia. However, this calculation no doubt has a high risk of underestimation due to unreported patients. In addition, it is of note that our patient was 61 years old. Since the age of recipients, and hence of related donors, can be expected to increase with the establishment of safer transplantation procedures such as nonmyeloablative approaches, 20 it is increasingly important to evaluate whether previous data on the safety of donors are applicable to an older population. In the face of the difficult situation of promoting an immediate worldwide prospective study, what must be urged is, at the very least, to ask all physicians to report every case that is similar to ours. /well in 100 ml of RPMI/10% FCS either with G-CSF (50 ng/ml), GM-CSF (50 ng/ml), IL-3 (50 ng/ml), or stem cell SCF (50 ng/ml) for 36, 60, or 84 h and analyzed by standard MTT assay. The data were expressed as means7s.d. of triplicate cultures. Effects of hematopoietic growth factors on growth curves of leukemia cells (b). Leukemia cells from the patient were cultured at 2 Â 10 6 /ml in RPMI/10% FCS containing no cytokine (closed square), SCF (open square), G-CSF (closed circle), G-CSF and SCF (open circle) or G-CSF, SCF, and IL-3 (asterisk) for 3 weeks. All the growth factors were used at 10 ng/ml and were freshly added twice a week. Half of the medium was replaced every week. The cells were counted with a coulter counter and represented as ratios to the initial cell numbers.
